# A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy

> **NCT04445220** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sentien Biotechnologies, Inc.** · enrollment: 22 (estimated)

## Conditions studied

- COVID-19
- Acute Kidney Injury
- Sepsis

## Interventions

- **BIOLOGICAL:** SBI-101

## Key facts

- **NCT ID:** NCT04445220
- **Lead sponsor:** Sentien Biotechnologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-19
- **Primary completion:** 2022-03
- **Final completion:** 2022-09
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2022-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04445220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04445220, "A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04445220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*